Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

In the years since I/O won­der drug Keytru­da’s ini­tial ap­proval, Mer­ck has struck an ag­gres­sive clin­i­cal tri­al pro­gram, which is now firm­ly fo­cused on ear­li­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.